Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

P-422: Outcomes in patients not receiving add-on therapy in the study on cognition and prognosis in the elderly (scope)

Title: P-422: Outcomes in patients not receiving add-on therapy in the study on cognition and prognosis in the elderly (scope)
Authors: Zanchetti, Alberto; Skoog, Ingmar; Elmfeldt, Dag; Hofman, Albert; Olofsson, Bertil; Trenkwalder, Peter; Lithell, Hans
Publisher Information: Oxford University Press
Publication Year: 2004
Collection: HighWire Press (Stanford University)
Subject Terms: Abstracts
Description: The Study on COgnition and Prognosis in the Elderly (SCOPE) was the first large-scale clinical trial to determine the effects of angiotensin II type 1 receptor blockade on cardiovascular and cognitive outcomes in elderly patients with mild to moderate hypertension. The present analysis evaluates clinical outcomes in SCOPE in patients who did not receive add-on antihypertensive therapy after randomization, i.e. in patients that best reflect the original intention of a placebo controlled trial. Patients randomized in SCOPE were aged 70–89 years, with systolic blood pressure 160–179 mmHg and/or diastolic blood pressure 90–99 mmHg, and preserved cognitive function. Out of 4,937 patients in SCOPE, 2,098 did not receive add-on therapy, and of these 1,253 patients received candesartan 8–16 mg once daily, and 845 placebo. Mean follow-up was 3.7 and 3.5 years, respectively. The primary outcome measure in SCOPE was major cardiovascular events, defined as the composite of cardiovascular mortality, non-fatal stroke and non-fatal myocardial infarction. Secondary outcomes included total mortality, cardiovascular mortality, and cognitive function. The treatment groups were generally well balanced for baseline characteristics. Blood pressure fell by 21.8/11.0 mmHg with candesartan and by 17.2/8.4 mmHg with placebo (difference between groups 4.7/2.6 mmHg, p
Document Type: text
File Description: text/html
Language: English
Relation: http://ajh.oxfordjournals.org/cgi/content/short/17/S1/188A-a; http://dx.doi.org/10.1016/j.amjhyper.2004.03.496
DOI: 10.1016/j.amjhyper.2004.03.496
Availability: http://ajh.oxfordjournals.org/cgi/content/short/17/S1/188A-a; https://doi.org/10.1016/j.amjhyper.2004.03.496
Rights: Copyright (C) 2004, American Journal of Hypertension, Ltd.
Accession Number: edsbas.2F4EA137
Database: BASE